Literature DB >> 10364231

PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase.

J C Amé1, V Rolli, V Schreiber, C Niedergang, F Apiou, P Decker, S Muller, T Höger, J Ménissier-de Murcia, G de Murcia.   

Abstract

Poly(ADP-ribosylation) is a post-translational modification of nuclear proteins in response to DNA damage that activates the base excision repair machinery. Poly(ADP-ribose) polymerase which we will now call PARP-1, has been the only known enzyme of this type for over 30 years. Here, we describe a cDNA encoding a 62-kDa protein that shares considerable homology with the catalytic domain of PARP-1 and also contains a basic DNA-binding domain. We propose to call this enzyme poly(ADP-ribose) polymerase 2 (PARP-2). The PARP-2 gene maps to chromosome 14C1 and 14q11.2 in mouse and human, respectively. Purified recombinant mouse PARP-2 is a damaged DNA-binding protein in vitro and catalyzes the formation of poly(ADP-ribose) polymers in a DNA-dependent manner. PARP-2 displays automodification properties similar to PARP-1. The protein is localized in the nucleus in vivo and may account for the residual poly(ADP-ribose) synthesis observed in PARP-1-deficient cells, treated with alkylating agents or hydrogen peroxide.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364231     DOI: 10.1074/jbc.274.25.17860

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  230 in total

1.  Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1.

Authors:  M D Vodenicharov; F R Sallmann; M S Satoh; G G Poirier
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

Review 2.  Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.

Authors:  Sook Ryun Park; Alice Chen
Journal:  Hematol Oncol Clin North Am       Date:  2012-06       Impact factor: 3.722

Review 3.  Microirradiation techniques in radiobiological research.

Authors:  Guido A Drexler; Miguel J Ruiz-Gómez
Journal:  J Biosci       Date:  2015-09       Impact factor: 1.826

4.  Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.

Authors:  Yong Tang; Hossein A Hamed; Andrew Poklepovic; Yun Dai; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2012-05-17       Impact factor: 4.436

5.  Cytokine-mediated β-cell damage in PARP-1-deficient islets.

Authors:  Teresa Andreone; Gordon P Meares; Katherine J Hughes; Polly A Hansen; John A Corbett
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-04-24       Impact factor: 4.310

6.  Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.

Authors:  Martín C Abba; Yuhui Hu; Carla C Levy; Sally Gaddis; Frances S Kittrell; Jamal Hill; Reid P Bissonnette; Powel H Brown; Daniel Medina; C Marcelo Aldaz
Journal:  Cancer Prev Res (Phila)       Date:  2009-01-27

7.  Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.

Authors:  Stefani N Thomas; Lijun Chen; Yang Liu; Naseruddin Höti; Hui Zhang
Journal:  J Proteome Res       Date:  2017-09-14       Impact factor: 4.466

8.  Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.

Authors:  Lisa Rank; Sebastian Veith; Eva C Gwosch; Janine Demgenski; Magdalena Ganz; Marjolijn C Jongmans; Christopher Vogel; Arthur Fischbach; Stefanie Buerger; Jan M F Fischer; Tabea Zubel; Anna Stier; Christina Renner; Michael Schmalz; Sascha Beneke; Marcus Groettrup; Roland P Kuiper; Alexander Bürkle; Elisa Ferrando-May; Aswin Mangerich
Journal:  Nucleic Acids Res       Date:  2016-09-29       Impact factor: 16.971

Review 9.  The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways.

Authors:  Riekelt H Houtkooper; Carles Cantó; Ronald J Wanders; Johan Auwerx
Journal:  Endocr Rev       Date:  2009-12-09       Impact factor: 19.871

Review 10.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.